Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria

References

• Brodsky RA. Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia. Ann Intern Med. 2008;148(8):587–595.
   PubMed Web of Science ®Google Scholar
• Parker CJ. Historical aspects of paroxysmal nocturnal haemoglobinuria: defining the disease‟. Br J Haematol. 2002;117(1):3–22.
   PubMed Web of Science ®Google Scholar
• Rotoli B, Luzzatto L. Paroxysmal nocturnal haemoglobinuria. Baillieres Clin Haematol. 1989;2(1):113–138.
   PubMedGoogle Scholar
• Biswajit H, Pratim PP, Kumar ST, et al. Aplastic anemia: a common hematological abnormality among periph-eral pancytopenia. N Am J Med Sci. 2012;4(9):384–388.
   PubMedGoogle Scholar
• Sahin F, Ozkan MC, Mete NG, et al. Multidisciplinary clinical management of paroxysmal nocturnal hemoglobinuria. Am J Blood Res. 2015;15(1):1–9.
   Google Scholar
• Shah N, and Bhatt H. Paroxysmal nocturnal hemoglobinuria. 2021 Aug 9. In: StatPearls [Internet. In: StatPearls Publishing: Treasure Island (FL); 2021 Jan. Available from: http://www.ncbi.nlm.nih.gov/books/NKB562292
   Google Scholar
• Gulbis B, Eleftheriou A, Angastiniotis M, et al. Epidemiology of rare anaemias in Europe. Adv Exp Med Biol. 2010;686:375–396.
   PubMed Web of Science ®Google Scholar
• Luzzatto L. PNH from mutations of another PIG gene. Blood. 2013 Aug 15;122(7):1099–1100.
   PubMed Web of Science ®Google Scholar
• Pramoonjago P, Pakdeesuwan K, Siripanyaphinyo U, et al. Genotypic, immunophenotypic and clinical features of Thai patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1999;105(2):497–504.
   PubMed Web of Science ®Google Scholar
• Boccuni P, Del Vecchio L, Di Noto R, et al. Glycosyl phosphatidylinositol (GPI)-anchored molecules and the pathogenesis of paroxysmal nocturnal hemoglobinuria. Crit Rev Oncol Hematol. 2000;33:25–43.
   PubMed Web of Science ®Google Scholar
• Bessler M, Mason PJ, Hillmen P, et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J. 1994;13(1):110–117.
   PubMed Web of Science ®Google Scholar
• Oni BS, Osunkoya BO, Luzzatto L. Paroxysmal nocturnal hemoglobinuria: evidence for monoclonal origin of abnormal red cells. Blood. 1970;36(2):145–152.
   PubMed Web of Science ®Google Scholar
• Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993 May 21;73(4):703–711.
   PubMed Web of Science ®Google Scholar
• Luzzatto L, Bessler M, Rotoli B. Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise? Cell. 1997;88(1):1–4.
   PubMed Web of Science ®Google Scholar
• Hirose S, Ravi L, Prince GM, et al. Synthesis of mannosylglucosaminylinositol phospholipids in normal but not paroxysmal nocturnal hemoglobinuria cells. Proc Natl Acad Sci USA. 1992;89(13):6025–6029.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Takeda J, Hirose S, et al. Deficient biosynthesis of N- acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria. J Exp Med. 1993;177(2):517–521.
   PubMed Web of Science ®Google Scholar
• Nicholson-Weller A, March JP, Rosenfeld SI, et al. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA. 1983;80(16):5066–5070.
   PubMed Web of Science ®Google Scholar
• Nicholson-Weller A, Spicer DB, Austen KF, et al. Deficiency of the complement regulatory protein, “decay-accelerating factor,” on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1985;312(17):1091–1097.
   PubMed Web of Science ®Google Scholar
• Burge J, Nicholson-Weller A, Austen KF. Isolation of C4-binding protein from Guinea pig plasma and demonstration of its function as a control protein of the classical complement pathway C3 convertase. J Immunol. 1981;126:232–235.
   PubMed Web of Science ®Google Scholar
• Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med. 1984;160(5):1558–1578.
   PubMed Web of Science ®Google Scholar
• Shin ML, Hänsch G, Hu VW, et al. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9. J Immunol. 1986;136:1777–1782.
   PubMed Web of Science ®Google Scholar
• Zalman LS, Wood LM, Müller-Eberhard HJ. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci USA. 1986;83(18):6975–6979.
   PubMed Web of Science ®Google Scholar
• Risitano AM, and Rotoli B. Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history end treatment options in era of biological agents. Biologics. 2008;2(2):205–222.
   Google Scholar
• Gargiulo L, Papaioannou M, Sica M, et al. Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria. Blood. 2013 Apr 4;121(14):2753–2761.
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Zaimoku Y, Scappini B, et al. Glycosylphosphatidylinositol-specific T cells, IFN-γ-producing T cells, and pathogenesis of idiopathic aplastic anemia. Blood. 2017 Jan 19;129(3):388–392.
   PubMed Web of Science ®Google Scholar
• Parker C, Omine M, Richards S, et al. International PNH Interest Group. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005Dec1;106(12):3699–3709.
   PubMed Web of Science ®Google Scholar
• Hill A, Rother RP, Arnold L, et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica. 2010;95(4):567–573.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113(17):4094–4100.
   PubMed Web of Science ®Google Scholar
• Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014 Oct 30;124(18):2804–2811.
   PubMed Web of Science ®Google Scholar
• Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2009 Jun 25;113(26):6522–6527.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350(6):552–559.
   PubMed Web of Science ®Google Scholar
• Hill A, Hillmen P, Richards SJ, et al. Sustained response and longterm safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005a;106(7):2559–2565.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–1243.
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840–1847.
   PubMed Web of Science ®Google Scholar
• Severe Aplastic Anemia Working Party of the European Group for Bone Marrow Transplantation, Debureaux PE, Kulasekararaj AG, Cacace F, et al. Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study. Bone Marrow Transplant. 2021 Oct;56(10):2600–2602.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Marotta S, Ricci P, et al. on behalf of the Severe Aplastic Anemia Working Party of the European group for Bone Marrow Transplantation. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol 2019 Jun 14;10: 1157.
   PubMed Web of Science ®Google Scholar
• Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. NEngl J Med. 2014;370(7):632–639.
   PubMed Web of Science ®Google Scholar
• de Latour R P, Fremeaux-Bacchi V, Porcher R, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015;125:775–783.
   PubMed Web of Science ®Google Scholar
• Sica M, Rondelli T, Ricci P, et al. R. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes. J Hematol Oncol. 2017;10(1):126.
   PubMedGoogle Scholar
• Risitano AM, Marotta S. Therapeutic complement inhibition in complement-mediated hemolytic anemias: past, present and future. Sem Immunol. 2016;28(3):223–240.
   PubMed Web of Science ®Google Scholar
• Kelly R, Arnold L, Richards S, et al. Modification of the eculizumab dose to successfully manage intravascular breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;112:3441.
   Web of Science ®Google Scholar
• Risitano AM. Paroxysmal nocturnal hemoglobinuria and other complement mediated hematological disorders. Immunobiology. 2012;217(11):1080–1087.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Hill A, Ricci P, et al. Paroxysmal nocturnal hemoglobinuria (PNH) in the eculizumab era: the bedside and beyond. Haematologica. 2007;92:89.
   Web of Science ®Google Scholar
• Risitano AM, Notaro R, Luzzatto L, et al. Paroxysmal nocturnal hemoglobinuria–hemolysis before and after eculizumab. N Engl J Med. 2010;363(23):2270–2272.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Marando L, Seneca E, et al. Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab. Blood. 2008;112(2):449–451.
   PubMed Web of Science ®Google Scholar
• Araten DJ, Iori AP, Brown K, et al. Selective splenic artery embolization for the treatment of thrombocytopenia and hypersplenism in paroxysmal nocturnal hemoglobinuria. J Hematol Oncol. 2014;7(1):27.
   PubMedGoogle Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT03500549
   Google Scholar
• Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus Eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021 Mar 18;384(11):1028–1037.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Pegcetacoplan: first approval. Drugs. 2021 Aug;81(12):1423–1430.
   PubMed Web of Science ®Google Scholar
• de Latour RP, Mary JY, Salanoubat C, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112(8):3099–3106.
   PubMed Web of Science ®Google Scholar
• de Latour R P, Schrezenmeier H, Bacigalupo A, et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica. 2012;97(11):1666–1673.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428–1436.
   PubMed Web of Science ®Google Scholar
• Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: a novel antiC5 antibody with extended duration of action. PLoS ONE. 2018;13(4):e0195909.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT02598583
   Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available from: https://clinicaltrials.gov/ct2/show/NCT02605993
   Google Scholar
• Röth A, Rottinghaus ST, Hill A, et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. Blood Adv. 2018 Sep 11;2(17):2176–2185.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT02946463
   Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT03056040
   Google Scholar
• Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019 Feb 7;133(6):530–539.
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Hill A, and Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5- inhibitor-experienced adult patients with PNH: the 302 study. Blood. 133(6): 540–549. 2018.
   PubMed Web of Science ®Google Scholar
• McKeage K. Ravulizumab: first global approval. Drugs. 2019 Feb;79(3):347–352.
   PubMed Web of Science ®Google Scholar
• Röth A, Nishimura JI, Nagy Z, et al. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020 Mar 19;135(12):912–920.
   PubMed Web of Science ®Google Scholar
• Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014 Feb 13;370(7):632–639.
   PubMed Web of Science ®Google Scholar
• Fukuzawa T, Sampei Z, Haraya K, et al. Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Sci Rep. 2017 Apr 24;7(1):1080.
   PubMedGoogle Scholar
• Sampei Z, Haraya K, Tachibana T, et al. Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody. PLoS One. 2018 Dec 28;13(12):e0209509.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT03157635
   Google Scholar
• Roth A, Zsolt N, Egyed M, et al. The SMART-IgG Anti-hC5 antibody (SKY59/RO7112689) has favorable PK, PD, subcutaneous bioavailability, and safety profile in phase I HV study. Blood. 2017;130:4750. 92.
   PubMed Web of Science ®Google Scholar
• Roth A, Egyed M, Ichikawa S, et al. The SMART Anti-hC5 antibody (SKY59/RO7112689) shows good safety and efficacy in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood. 2018;132(Supplement 1):535.
   Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT04654468
   Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT04432584
   Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT04434092
   Google Scholar
• Ueda Y, Osato M, Weston-Davies W, et al. Coversin blocked in vitro hemolysis in an eculizumab-resistant PNH patient with the C5 polymorphism (c.2654G>A). Blood. 2015;126:2138.
   PubMed Web of Science ®Google Scholar
• Weston-Davies WH, Nunn MA, Pinto FO, et al. Clinical and immunological characterization of coversin, a novel small protein inhibitor of complement C5 with potential as a therapeutic agent in PNH and other complement mediated disorders. Blood. 2014;124(21):4280.
   Web of Science ®Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT02591862
   Google Scholar
• Hill A, Windyga J, Robak T, et al. Results of COBALT, a phase II clinical trial of coversin in PNH. HemaSphere. 2018;2:109. Poster presentation during EHA23.
   Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT03588026
   Google Scholar
• Grossi FV, Bedwell P, Deschatelets P, et al. APL-2, a complement C3 inhibitor for the potential treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): phase I data from two completed studies in healthy volunteers. Blood. 2016;128(22):1251.
   Web of Science ®Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT02264639
   Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT02588833
   Google Scholar
• de Castro C, Grossi F, Weitz IC, et al. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. Am J Hematol. 2020 Nov;95(11):1334–1343.
   PubMed Web of Science ®Google Scholar
• Wong RSM, Pullon HWH, Deschatelets P, et al. Inhibition of C3 with APL-2 results in normalisation of markers of intravascular and extravascular hemolysis in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood. 2018;132(Supplement 1):2314.
   PubMedGoogle Scholar
• Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2021 Mar 18;384(11):1028–1037.
   PubMed Web of Science ®Google Scholar
• Schubart A, Anderson K, Mainolfi N, et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7926–7931.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT03439839
   Google Scholar
• Risitano AM, Röth A, Soret J, et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol. 2021 May;8(5):e344–e354.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT04558918
   Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT04820530
   Google Scholar
• Morgan BP, Thanassi J, Podos S, et al. Novel small- molecule inhibitors targeting complement factor D for therapy of paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(21):4817.
   Web of Science ®Google Scholar
• Wiles J, Podos S, Thanassi J, et al. Preclinical evaluation of orally bioavailable small-molecule inhibitors of complement factor D as a potential treatment for paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(21):4819.
   Web of Science ®Google Scholar
• Ellis-Pegler RB, Schwabe C, Ajari I, et al. An orally administered small molecule factor D inhibitor (ACH-4471) for treatment of PNH and complement diseases: preliminary phase I results in healthy volunteers. Haematologica. 2016;101:416.
   Web of Science ®Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT03053102
   Google Scholar
• Risitano AM, Kulasekararaj AG, Lee JW, et al. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica. 2020 Oct 29; DOI:https://doi.org/10.3324/haematol.2020.261826.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT03472885
   Google Scholar
• Kulasekararaj A, Risitano AM, Maciejewski JP, et al. A phase 2 open-label study of danicopan (ACH-0144471) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have an inadequate response to eculizumab monotherapy. Blood. 2019;134(Supplement_1):3514.
   Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT04170023
   Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available online at: https://clinicaltrials.gov/ct2/show/NCT04469465
   Google Scholar
• Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007 Dec 1;110(12):4123–4128.
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011 Jun 23;117(25):6786–6792.
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Peffault de Latour R, Rottinghaus ST, et al. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. 2021 Jan 1;106(1):230–237.
   PubMed Web of Science ®Google Scholar
• Risitano AM, and Peffault de Latour R. How we(‘ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future. Br J Haematol. 2021 Aug 5; 196:288–303.
   PubMed Web of Science ®Google Scholar